<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <p content-type="self-citation">
  <mixed-citation publication-type="self-citation" id="rmv2143-cit-9001">
   <string-name>
    <surname>Valle</surname>
    <given-names>C</given-names>
   </string-name>, 
   <string-name>
    <surname>Martin</surname>
    <given-names>B</given-names>
   </string-name>, 
   <string-name>
    <surname>Touret</surname>
    <given-names>F</given-names>
   </string-name>, et al. 
   <article-title>Drugs against 
    <styled-content style="fixed-case" toggle="no">SARS‐CoV</styled-content>‐2: What do we know about their mode of action?
   </article-title>
   <source xml:lang="en">Rev Med Virol</source>. 
   <year>2020</year>;
   <elocation-id>e2143</elocation-id>
   <pub-id pub-id-type="doi">10.1002/rmv.2143</pub-id>
   <pub-id pub-id-type="pmid">32779326</pub-id>
  </mixed-citation>
 </p>
 <fn-group>
  <fn id="rmv2143-note-1002">
   <p>
    <bold>Funding information</bold> European Union's Horizon 2020 research and innovation programme, Grant/Award Number: 101003627; SCORE project H2020 SC1‐PHE‐Coronavirus194 2020, Grant/Award Number: 101003627; Fondation pour la Recherche Médicale; Inserm
   </p>
  </fn>
 </fn-group>
</notes>
